Literature DB >> 30416773

Fibrinogen as a potential biomarker for clinical phenotype in patients with chronic obstructive pulmonary disease.

Tae Hoon Kim1,2, Dong Kyu Oh1, Yeon-Mok Oh1, Sei Won Lee1, Sang Do Lee1, Jae Seung Lee1.   

Abstract

BACKGROUND: Under the Food and Drug Administration's drug development tool qualification program, fibrinogen is the first biomarker drug development tool used in chronic obstructive pulmonary disease (COPD). However, the correlation between fibrinogen and exacerbations among Korean patients with COPD remains unclear.
METHODS: In this retrospective cross-sectional study, we included patients with COPD for whom plasma fibrinogen assessment results, without exacerbation, were available. Then, we compared subgroups according to fibrinogen level (threshold: 350 mg/dL). We used multivariate linear regression analysis to investigate the clinical phenotype of COPD with high fibrinogen level, analyzed the correlation between the COPD severity indexes and fibrinogen level.
RESULTS: Of 140 patients, we confirmed 48 (34.3%) patients in the high-level fibrinogen group. The high-level group demonstrated a medical history of more exacerbations than the low-level group. Lung functions [forced expiratory volume in 1 s (FEV1), forced vital capacity, and 6-minute walk distance] were more deteriorated in the high-level group. Multivariate regression analysis revealed that fibrinogen level was associated with high COPD assessment test score, and experience of exacerbation. Fibrinogen level exhibited a statistically significant positive correlation with COPD severity indexes.
CONCLUSIONS: High fibrinogen level seems to reflect frequent exacerbation and severe symptomatic phenotypes in Korean patients with COPD.

Entities:  

Keywords:  Biomarkers; chronic obstructive lung disease; fibrinogen; inflammation

Year:  2018        PMID: 30416773      PMCID: PMC6196189          DOI: 10.21037/jtd.2018.08.52

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   3.005


  29 in total

1.  Guidelines on fibrinogen assays.

Authors:  Ian J Mackie; Steven Kitchen; Samuel J Machin; Gordon D O Lowe
Journal:  Br J Haematol       Date:  2003-05       Impact factor: 6.998

Review 2.  How to measure comorbidity. a critical review of available methods.

Authors:  Vincent de Groot; Heleen Beckerman; Gustaaf J Lankhorst; Lex M Bouter
Journal:  J Clin Epidemiol       Date:  2003-03       Impact factor: 6.437

3.  Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD.

Authors:  Koichi Nishimura; Takateru Izumi; Mitsuhiro Tsukino; Toru Oga
Journal:  Chest       Date:  2002-05       Impact factor: 9.410

Review 4.  Erythrocyte Sedimentation Rate and C-reactive Protein Measurements and Their Relevance in Clinical Medicine.

Authors:  Christopher Bray; Lauren N Bell; Hong Liang; Rasha Haykal; Farah Kaiksow; Joseph J Mazza; Steven H Yale
Journal:  WMJ       Date:  2016-12

Review 5.  Biomarkers of progression of chronic obstructive pulmonary disease (COPD).

Authors:  Janet G Shaw; Annalicia Vaughan; Annette G Dent; Phoebe E O'Hare; Felicia Goh; Rayleen V Bowman; Kwun M Fong; Ian A Yang
Journal:  J Thorac Dis       Date:  2014-11       Impact factor: 2.895

Review 6.  The chronic bronchitis phenotype in chronic obstructive pulmonary disease: features and implications.

Authors:  Victor Kim; Gerard J Criner
Journal:  Curr Opin Pulm Med       Date:  2015-03       Impact factor: 3.155

7.  Systemic inflammation in chronic obstructive pulmonary disease: a population-based study.

Authors:  Francisco Garcia-Rio; Marc Miravitlles; Joan B Soriano; Luis Muñoz; Enric Duran-Tauleria; Guadalupe Sánchez; Víctor Sobradillo; Julio Ancochea
Journal:  Respir Res       Date:  2010-05-25

8.  Reduced lung function in patients with abdominal aortic aneurysm is associated with activation of inflammation and hemostasis, not smoking or cardiovascular disease.

Authors:  F Gerald R Fowkes; Chantelle L C Anandan; Amanda J Lee; Felicity B Smith; Ioanna Tzoulaki; Ann Rumley; Janet T Powell; Gordon D O Lowe
Journal:  J Vasc Surg       Date:  2006-03       Impact factor: 4.268

9.  Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype.

Authors:  Alvar Agustí; Lisa D Edwards; Stephen I Rennard; William MacNee; Ruth Tal-Singer; Bruce E Miller; Jørgen Vestbo; David A Lomas; Peter M A Calverley; Emiel Wouters; Courtney Crim; Julie C Yates; Edwin K Silverman; Harvey O Coxson; Per Bakke; Ruth J Mayer; Bartolome Celli
Journal:  PLoS One       Date:  2012-05-18       Impact factor: 3.240

Review 10.  Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease.

Authors:  Annelyse Duvoix; Jenny Dickens; Imran Haq; David Mannino; Bruce Miller; Ruth Tal-Singer; David A Lomas
Journal:  Thorax       Date:  2012-06-28       Impact factor: 9.139

View more
  4 in total

1.  Vitamin D and Chronic Obstructive Pulmonary Disease: Biomarker Related to Outcomes.

Authors:  So Young Park; Kwang Ha Yoo
Journal:  J Korean Med Sci       Date:  2019-07-29       Impact factor: 2.153

2.  Endotype-driven prediction of acute exacerbations in chronic obstructive pulmonary disease (EndAECOPD): protocol for a prospective cohort study.

Authors:  Wei Xiao; Long-Yi Du; Bing Mao; Ti-Wei Miao; Juan-Juan Fu
Journal:  BMJ Open       Date:  2019-11-04       Impact factor: 2.692

3.  The clinical relevance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in chronic obstructive pulmonary disease with lung cancer.

Authors:  Aiping Ma; Guangdong Wang; Yan Du; Weixi Guo; Jiaxi Guo; Yi Hu; Dongyu Bai; Huiping Huang; Lianjin Zhuang; Jinhan Chen; Qun Liu
Journal:  Front Oncol       Date:  2022-09-27       Impact factor: 5.738

4.  Platelet indices in stable chronic obstructive pulmonary disease - association with inflammatory markers, comorbidities and therapy.

Authors:  Iva Hlapčić; Anita Somborac-Bačura; Sanja Popović-Grle; Andrea Vukić Dugac; Dunja Rogić; Ivana Rako; Tihana Žanić Grubišić; Lada Rumora
Journal:  Biochem Med (Zagreb)       Date:  2019-12-15       Impact factor: 2.313

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.